20.12
+0.36(+1.82%)
Currency In USD
| Previous Close | 19.76 |
| Open | 19.83 |
| Day High | 20.22 |
| Day Low | 19.57 |
| 52-Week High | 35.84 |
| 52-Week Low | 15.45 |
| Volume | 403,805 |
| Average Volume | 463,705 |
| Market Cap | 580.91M |
| PE | -105.89 |
| EPS | -0.19 |
| Moving Average 50 Days | 18.08 |
| Moving Average 200 Days | 24.73 |
| Change | 0.36 |
If you invested $1000 in Castle Biosciences, Inc. (CSTL) since IPO date, it would be worth $940.19 as of July 10, 2025 at a share price of $20.12. Whereas If you bought $1000 worth of Castle Biosciences, Inc. (CSTL) shares 5 years ago, it would be worth $481.92 as of July 10, 2025 at a share price of $20.12.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jun 19, 2025 11:00 AM GMT
FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 14, 2025, the Compensation Committee of its Boa
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
GlobeNewswire Inc.
Jun 16, 2025 8:30 PM GMT
Initial Development Project Targets Predicting Flares in Patients Diagnosed with Atopic DermatitisFRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests tha
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
GlobeNewswire Inc.
Jun 11, 2025 11:00 AM GMT
FRIENDSWOOD, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, founder, president and chief executive